Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2020 01:00 ET | Source: ObsEva SA

ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China

Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a sublicense agreement to develop and commercialize nolasiban...
January 07, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020

Geneva, Switzerland and Boston, MA – January 7, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
December 09, 2019 01:00 ET | Source: ObsEva SA

ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints93.9% responder rate for 200 mg with ABT (p < 0.001)56.7% responder rate for 100 mg without ABT (p < 0.001)Both doses...
December 06, 2019 16:30 ET | Source: ObsEva SA

ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019

Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
November 07, 2019 01:10 ET | Source: ObsEva SA

ObsEva Announces Third Quarter 2019 Financial Results

– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast...
November 07, 2019 01:00 ET | Source: ObsEva SA

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

Company to Discontinue Current Nolasiban IVF Program Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and...
November 06, 2019 16:50 ET | Source: ObsEva SA

Correction: ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
November 06, 2019 16:30 ET | Source: ObsEva SA

ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
November 06, 2019 01:00 ET | Source: ObsEva SA

ObsEva SA to Participate in Upcoming Investor Conferences

Geneva, Switzerland and Boston, MA – November 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
November 04, 2019 01:00 ET | Source: ObsEva SA

ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019

Geneva, Switzerland and Boston, MA –November 4, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...